Lv2
172 积分 2024-09-27 加入
Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody–Drug Conjugates
1个月前
已完结
Site-specific antibody labeling via endo-S2 mediated Fc glycan remodeling
3个月前
已关闭
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
3个月前
已完结
Process Development of Site-Specific Antibody–Drug Conjugates
4个月前
已完结
Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations
4个月前
已完结
From R&D to Clinical Supplies
4个月前
已完结
Antibody–Drug Conjugates: An Overview of theCMCand Characterization Process
4个月前
已完结
CMC Regulatory Considerations for Antibody-Drug Conjugates
4个月前
已完结
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
4个月前
已完结
From linker stability to linker fitness: redefining ADC design for clinical translation
4个月前
已关闭
皖公网安备34019202002308
